Notwithstanding positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from managed care entities. These insurers https://aadamyhdy899353.vblogetin.com/48143300/the-drug-faces-is-meeting-pharmacy-benefit-manager-hurdles-a-review-of-reimbursement-disputes